Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report identifies the key trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market landscape? – Identify, understand and capitalize.
Therapy Industry in the United Kingdom
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Introduction 7
2.1 Overview 7
2.2 Classification of Idiopathic Thrombocytopenic Purpura 7
2.3 Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura 8
2.4 Epidemiology 9
2.5 Clinical Symptoms 9
2.6 Diagnosis and Management of Idiopathic Thrombocytopenic Purpura 9
2.7 Treatment of Idiopathic Thrombocytopenic Purpura 11
2.8 GlobalData Pipeline Report Guidance 12
3 Idiopathic Thrombocytopenic Purpura Therapeutics - Market Characterization 13
3.1 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Global 13
3.2 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Global 14
3.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the US 15
3.4 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the US 16
3.5 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - the UK 17
3.6 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - the UK 18
3.7 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - France 19
3.8 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - France 20
3.9 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Germany 21
3.10 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Germany 22
3.11 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Italy 23
3.12 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Italy 24
3.13 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Spain 25
3.14 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Spain 26
3.15 Idiopathic Thrombocytopenic Purpura Therapeutics Market Size (2006-2011) - Japan 27
3.16 Idiopathic Thrombocytopenic Purpura Therapeutics Market Forecast (2011-2019) - Japan 28
3.16.1 Drivers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market 29
3.16.2 Barriers for the Idiopathic Thrombocytopenic Purpura Therapeutics Market 29
3.17 Key Events Impacting the Future Market 30
3.18 Opportunity and Unmet Need 31
3.19 Key Takeaway 32
4 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profiles for the Major Marketed Products in the Idiopathic Thrombocytopenic Purpura Therapeutics Market 34
4.3.1 Nplate (romiplostim) 34
4.3.2 Promacta/Revolade (eltrombopag) 34
4.4 Key Takeaway 35
5 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Pipeline Assessment 36
5.1 Overview 36
5.1.1 Strategic Pipeline Assessment 36
5.2 Idiopathic Thrombocytopenic Purpura Therapeutics Pipeline Analysis - Pipeline by Clinical Phases of Development 36
5.2.1 ITP Therapeutics - Phase III Clinical Pipeline 36
5.2.2 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Clinical Pipeline 37
5.2.3 Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Clinical Pipeline 37
5.2.4 Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline 37
5.3 Idiopathic Thrombocytopenic Purpura Therapeutics Market - Clinical Pipeline by Mechanism of Action 38
5.4 Idiopathic Thrombocytopenic Purpura Technology Trends Analytical Framework 39
5.5 Molecule Profile for Late-Stage Drugs under Clinical Development 40
5.5.1 IGIV3I 10% Grifols 40
5.5.2 Mabthera (rituximab) 41
5.6 Key Takeaway 41
6 Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials Mapping 42
6.1 Clinical Trials by Country 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Overall Sponsors 45
6.5 Prominent Sponsors 46
6.6 Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials 47
7 Idiopathic Thrombocytopenic Purpura Therapeutics - Strategic Assessment 48
7.1 Future Market Competition Scenario 48
8 Idiopathic Thrombocytopenic Purpura Therapeutics - Future Players 49
8.1 Introduction 49
8.2 Company Profiles 50
8.2.1 F. Hoffmann-La Roche 50
8.2.2 Grifols Biologicals Inc. 51
8.2.3 Amgen Inc. 51
8.2.4 GlaxoSmithKline plc 53
8.2.5 Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 55
9 Idiopathic Thrombocytopenic Purpura Therapeutics - Licensing and Partnership Deals 56
10 Idiopathic Thrombocytopenic Purpura Therapeutics - Appendix 57
10.1 Definitions 57
10.2 Acronyms 57
10.3 Research Methodology 58
10.3.1 Coverage 58
10.3.2 Secondary Research 58
10.3.3 Forecasting 59
10.3.4 Primary Research 61
10.3.5 Expert Panel Validation 62
10.4 Contact Us 62
10.5 Disclaimer 62
10.6 Bibliography 62
List of Tables
Table 1: Classification of Idiopathic Thrombocytopenic Purpura 7
Table 2: Prevalence of Idiopathic Thrombocytopenic Purpura, 2011 9
Table 3: Diagnostic Tools for Idiopathic Thrombocytopenic Purpura 10
Table 4: Treatment of Idiopathic Thrombocytopenic Purpura according to Haematological Societies Guidelines 11
Table 5: Characteristics of Existing Major Drugs for Idiopathic Thrombocytopenic Purpura 11
Table 6: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Revenue ($m), 2006 - 2011 13
Table 7: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Forecast ($m), 2011 - 2019 14
Table 8: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2006 - 2011 15
Table 9: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2011 - 2019 16
Table 10: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Revenue ($m), 2006 - 2011 17
Table 11: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Forecast ($m), 2011 - 2019 18
Table 12: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Revenue ($m), 2006 - 2011 19
Table 13: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Forecast ($m), 2011 - 2019 20
Table 14: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 21
Table 15: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 22
Table 16: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 23
Table 17: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 24
Table 18: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 25
Table 19: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 26
Table 20: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 27
Table 21: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 28
Table 22: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase III Pipeline 36
Table 23: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase II Pipeline 37
Table 24: Idiopathic Thrombocytopenic Purpura Therapeutics - Phase I/II Pipeline 37
Table 25: Idiopathic Thrombocytopenic Purpura Therapeutics - Pre-Clinical Pipeline 37
Table 26: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Country, 2011 42
Table 27: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Phase, 2011 43
Table 28: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Status, 2011 44
Table 29: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Overall Sponsors, 2011 45
Table 30: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Prominent Sponsors, 2011 46
Table 31: Idiopathic Thrombocytopenic Purpura Therapeutics - Top Companies Participating in Clinical Trials, 2011 47
Table 32: F. Hoffmann-La Roche - Idiopathic Thrombocytopenic Purpura Pipeline, 2011 50
Table 33: Grifols Biologicals Inc.- Idiopathic Thrombocytopenic Purpura Pipeline, 2011 51
Table 34: Amgen Inc. - Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 52
Table 35: GlaxoSmithKline plc - Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 54
Table 36: Other Companies in the Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 55
Table 37: Idiopathic Thrombocytopenic Purpura Therapeutics: Licensing and Partnership Deals 56
List of Figures
Figure 1: Pathophysiology of Chronic Idiopathic Thrombocytopenic Purpura 8
Figure 2: Management Algorithm for Idiopathic Thrombocytopenic Purpura 10
Figure 3: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Global, Revenue ($m), 2006-2011 13
Figure 4: ITP Therapeutics Market, Global, Forecast ($m), 2011 - 2019 14
Figure 5: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Revenue ($m), 2006 - 2011 15
Figure 6: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the US, Forecast ($m), 2011 - 2019 16
Figure 7: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Revenue ($m), 2006 - 2011 17
Figure 8: Idiopathic Thrombocytopenic Purpura Therapeutics Market, the UK, Forecast ($m), 2011 - 2019 18
Figure 9: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Revenue ($m), 2006 - 2011 19
Figure 10: Idiopathic Thrombocytopenic Purpura Therapeutics Market, France, Forecast ($m), 2011 - 2019 20
Figure 11: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 21
Figure 12: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 22
Figure 13: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 23
Figure 14: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 24
Figure 15: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 25
Figure 16: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 26
Figure 17: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 27
Figure 18: Idiopathic Thrombocytopenic Purpura Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 28
Figure 19: Idiopathic Thrombocytopenic Purpura Therapeutics, Key Events Impacting Future Market 30
Figure 20: Opportunity and Unmet Need in the First-line Treatment of Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 31
Figure 21:Opportunity and Unmet Need in the Second-line Treatment of Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2011 32
Figure 22: Idiopathic Thrombocytopenic Purpura Therapeutics Market - Strategic Competitor Assessment, 2011 33
Figure 23: Idiopathic Thrombocytopenic Purpura Therapeutics - Pipeline by Phase of Clinical Development, 2011 36
Figure 24: Idiopathic Thrombocytopenic Purpura Therapeutics, Clinical Pipeline by Mechanism of Action, 2011 38
Figure 25: Idiopathic Thrombocytopenic Purpura Therapeutics, Technology Trends Analytics Framework, 2011 39
Figure 26: Idiopathic Thrombocytopenic Purpura Therapeutics, Technology Trends Analytics Framework, Description, 2011 40
Figure 27: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Country, 2011 42
Figure 28: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Phase, 2011 43
Figure 29: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Status, 2011 44
Figure 30: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical Trials by Overall Sponsors, 2011 45
Figure 31: Idiopathic Thrombocytopenic Purpura Therapeutics - Clinical trials by Prominent Sponsors, 2011 46
Figure 32: Top Companies Participating in Idiopathic Thrombocytopenic Purpura Therapeutics Clinical Trials, 2011 47
Figure 33: Idiopathic Thrombocytopenic Purpura Therapeutics, Strategic Assessment, 2011 48
Figure 34: Idiopathic Thrombocytopenic Purpura Therapeutics Market - Future Players, 2011 49
Figure 35: GlobalData Market Forecasting Model 61
Companies mentioned
F. Hoffmann-La Roche
Grifols Biologicals Inc.
Amgen Inc.
GlaxoSmithKline plc
